{"pmid":32405629,"title":"COVID-19 and Cancer Patients.","text":["COVID-19 and Cancer Patients.","COVID-19 has now been declared a global pandemic with evolving incidence rates and fatalities. It is important to identify vulnerable populations who will be impacted most by this pandemic leading to higher mortality rates compared to the general healthy population. Although older patients and patients with co-morbidities fall into this vulnerable group, patients with hematologic and oncologic malignancies on active cytotoxic treatments are at even greater risk as they are both myelosuppressed and immunosuppressed. In addition to following the universal guidelines recommended by the Centers for Disease Control (CDC), it is important to also institute guidelines for cancer centers to help protect this vulnerable population. We review the current data, risks, and recommendations for COVID-19 in cancer patients.","Cancer Med J","Patel, Rajvi","Park, Jennifer","Shah, Ankit","Wasif Saif, Muhammad","32405629"],"abstract":["COVID-19 has now been declared a global pandemic with evolving incidence rates and fatalities. It is important to identify vulnerable populations who will be impacted most by this pandemic leading to higher mortality rates compared to the general healthy population. Although older patients and patients with co-morbidities fall into this vulnerable group, patients with hematologic and oncologic malignancies on active cytotoxic treatments are at even greater risk as they are both myelosuppressed and immunosuppressed. In addition to following the universal guidelines recommended by the Centers for Disease Control (CDC), it is important to also institute guidelines for cancer centers to help protect this vulnerable population. We review the current data, risks, and recommendations for COVID-19 in cancer patients."],"journal":"Cancer Med J","authors":["Patel, Rajvi","Park, Jennifer","Shah, Ankit","Wasif Saif, Muhammad"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32405629","source":"PubMed","week":"202020|May 11 - May 17","keywords":["covid-19","cancer patients","cough","fever","immunosuppressed","influenza","pneumonia","sepsis","shortness of breath"],"topics":["Prevention"],"weight":1,"_version_":1666802845502930944,"score":9.490897,"similar":[{"pmid":32453656,"title":"Management of Lung Cancer During the COVID-19 Pandemic.","text":["Management of Lung Cancer During the COVID-19 Pandemic.","Coronavirus disease 2019 (COVID-19) has had a devastating impact around the world. With high rates of transmission and no curative therapies or vaccine yet available, the current cornerstone of management focuses on prevention by social distancing. This includes decreased health care contact for patients. Patients with lung cancer are a particularly vulnerable population, where the risk of mortality from cancer must now be balanced by the potential risk of a life-threatening infection. In these unprecedented times, a collaborative and multidisciplinary approach is required to streamline but not compromise care. We have developed guidelines at our academic cancer center to standardize management of patients with lung cancer across our health care system and provide guidance to the larger oncology community. We recommend that general principles of lung cancer treatment continue to be followed in most cases where delays could result in rapid cancer progression. We recognize that our recommendations may change over time based on clinical resources and the evolving nature of the COVID-19 pandemic. In principle, however, treatment paradigms must continue to be individualized, with careful consideration of risks and benefits of continuing or altering lung cancer-directed therapy.","JCO Oncol Pract","Singh, Aditi P","Berman, Abigail T","Marmarelis, Melina E","Haas, Andrew R","Feigenberg, Steven J","Braun, Jennifer","Ciunci, Christine A","Bauml, Joshua M","Cohen, Roger B","Kucharczuk, John C","Shulman, Lawrence N","Langer, Corey J","Aggarwal, Charu","32453656"],"abstract":["Coronavirus disease 2019 (COVID-19) has had a devastating impact around the world. With high rates of transmission and no curative therapies or vaccine yet available, the current cornerstone of management focuses on prevention by social distancing. This includes decreased health care contact for patients. Patients with lung cancer are a particularly vulnerable population, where the risk of mortality from cancer must now be balanced by the potential risk of a life-threatening infection. In these unprecedented times, a collaborative and multidisciplinary approach is required to streamline but not compromise care. We have developed guidelines at our academic cancer center to standardize management of patients with lung cancer across our health care system and provide guidance to the larger oncology community. We recommend that general principles of lung cancer treatment continue to be followed in most cases where delays could result in rapid cancer progression. We recognize that our recommendations may change over time based on clinical resources and the evolving nature of the COVID-19 pandemic. In principle, however, treatment paradigms must continue to be individualized, with careful consideration of risks and benefits of continuing or altering lung cancer-directed therapy."],"journal":"JCO Oncol Pract","authors":["Singh, Aditi P","Berman, Abigail T","Marmarelis, Melina E","Haas, Andrew R","Feigenberg, Steven J","Braun, Jennifer","Ciunci, Christine A","Bauml, Joshua M","Cohen, Roger B","Kucharczuk, John C","Shulman, Lawrence N","Langer, Corey J","Aggarwal, Charu"],"date":"2020-05-27T11:00:00Z","year":2020,"_id":"32453656","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1200/OP.20.00286","topics":["Prevention","Treatment"],"weight":1,"_version_":1667983494587875328,"score":204.03432},{"pmid":32467810,"pmcid":"PMC7250517","title":"Coronavirus Disease 2019 (COVID-19) in Cancer Patients.","text":["Coronavirus Disease 2019 (COVID-19) in Cancer Patients.","The Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become the most talked-about clinical entity in early 2020. As an infection that spreads easily and has a significant mortality rate, it has caused global panic rarely seen before. Many of the measures taken by governments worldwide will have long-lasting impacts on the wellbeing of the population at large. It has been widely reported that the most vulnerable patients have been most negatively affected by SARS-CoV-2 (COVID-19). In this study, we have tried to search the currently available data on the outcomes of infected cancer patients. Most of the data points to the very challenging nature of treating such patients. Their overall outcomes seem to be worse than in the general population, and it may be difficult to differentiate which potential complications are a result of the primary oncologic disease versus the infection. Management presents its own set of challenges, including but not limited to, deciding whether postponing cancer treatment until the infection resolves is going to benefit the patient and how to organize all aspects of patient care when social contact is as limited as it is for patients newly diagnosed with COVID-19. We believe that as more data becomes available, it is going to be necessary to publish detailed guidelines on how to approach this unique clinical challenge.","Cureus","Cancarevic, Ivan","Tathineni, Praveena","Malik, Bilal Haider","32467810"],"abstract":["The Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become the most talked-about clinical entity in early 2020. As an infection that spreads easily and has a significant mortality rate, it has caused global panic rarely seen before. Many of the measures taken by governments worldwide will have long-lasting impacts on the wellbeing of the population at large. It has been widely reported that the most vulnerable patients have been most negatively affected by SARS-CoV-2 (COVID-19). In this study, we have tried to search the currently available data on the outcomes of infected cancer patients. Most of the data points to the very challenging nature of treating such patients. Their overall outcomes seem to be worse than in the general population, and it may be difficult to differentiate which potential complications are a result of the primary oncologic disease versus the infection. Management presents its own set of challenges, including but not limited to, deciding whether postponing cancer treatment until the infection resolves is going to benefit the patient and how to organize all aspects of patient care when social contact is as limited as it is for patients newly diagnosed with COVID-19. We believe that as more data becomes available, it is going to be necessary to publish detailed guidelines on how to approach this unique clinical challenge."],"journal":"Cureus","authors":["Cancarevic, Ivan","Tathineni, Praveena","Malik, Bilal Haider"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32467810","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.7759/cureus.7835","keywords":["2019 novel coronavirus","cancer","cancer patients","coronavirus disease","coronavirus pandemic","lung cancer","novel coronavirus","sars-cov-2","severe acute respiratory syndrome coronavirus 2","wuhan coronavirus"],"topics":["Prevention"],"weight":1,"_version_":1668167110007717888,"score":198.30125},{"pmid":32344317,"pmcid":"PMC7174983","title":"Cancer patients and research during COVID-19 pandemic: A systematic review of current evidence.","text":["Cancer patients and research during COVID-19 pandemic: A systematic review of current evidence.","The novel coronavirus, also known as SARS-Cov-2 or COVID-19 has become a worldwide threat and the major healthcare concern of the year 2020. Cancer research was directly affected by the emerging of this disease. According to some Chinese studies, cancer patients are more vulnerable to COVID-19 complications. This observation led many oncologists to change their daily practice in cancer care, without solid evidence and recommendations. Moreover, the COVID-19 manifestations as well as its diagnosis are particular in this special population. In this review paper we expose the challenges of cancer management in the era of SARS-CoV-2, the epidemiological, clinical, pathological and radiological characteristics of the disease in cancer patients and its outcomes on this population. Finally, we focus on strategies that are followed in cancer management with review of national and international guidelines.","Crit Rev Oncol Hematol","Moujaess, Elissar","Kourie, Hampig Raphael","Ghosn, Marwan","32344317"],"abstract":["The novel coronavirus, also known as SARS-Cov-2 or COVID-19 has become a worldwide threat and the major healthcare concern of the year 2020. Cancer research was directly affected by the emerging of this disease. According to some Chinese studies, cancer patients are more vulnerable to COVID-19 complications. This observation led many oncologists to change their daily practice in cancer care, without solid evidence and recommendations. Moreover, the COVID-19 manifestations as well as its diagnosis are particular in this special population. In this review paper we expose the challenges of cancer management in the era of SARS-CoV-2, the epidemiological, clinical, pathological and radiological characteristics of the disease in cancer patients and its outcomes on this population. Finally, we focus on strategies that are followed in cancer management with review of national and international guidelines."],"journal":"Crit Rev Oncol Hematol","authors":["Moujaess, Elissar","Kourie, Hampig Raphael","Ghosn, Marwan"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32344317","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.critrevonc.2020.102972","keywords":["covid-19","cancer patients","oncology","research","systematic review"],"locations":["Chinese"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Diagnosis","Prevention"],"weight":1,"_version_":1666138495791398913,"score":193.81725},{"pmid":32357994,"title":"Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System.","text":["Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System.","Cancer patients are presumed to be at increased risk from COVID-19 infection fatality due to underlying malignancy, treatment-related immunosuppression, or increased comorbidities. A total of 218 COVID-19 positive patients from March 18th-April 8th, 2020 with a malignant diagnosis were identified. A total of 61 (28%) cancer patients died from COVID-19 with a case fatality rate (CFR) of 37% (20/54) for hematologic malignancies and 25% (41/164) for solid malignancies. 6/11 (55%) lung cancer patients died from COVID-19 disease. Increased mortality was significantly associated with older age, multiple comorbidities, need for ICU support, and elevated levels of D-Dimers, LDH and lactate on multivariable analysis. Age-adjusted CFRs in cancer patients compared to non-cancer patients at our institution and NYC reported a significant increase in case fatality for cancer patients. These data suggest the need for proactive strategies to reduce likelihood of infection and improve early identification in this vulnerable patient population.","Cancer Discov","Mehta, Vikas","Goel, Sanjay","Kabarriti, Rafi","Cole, Daniel","Goldfinger, Mendel","Acuna-Villaorduna, Ana","Pradhan, Kith","Thota, Raja","Reissman, Stan","Sparano, Joseph A","Gartrell, Benjamin A","Smith, Richard V","Ohri, Nitin","Garg, Madhur","Racine, Andrew D","Kalnicki, Shalom","Perez-Soler, Roman","Halmos, Balazs","Verma, Amit","32357994"],"abstract":["Cancer patients are presumed to be at increased risk from COVID-19 infection fatality due to underlying malignancy, treatment-related immunosuppression, or increased comorbidities. A total of 218 COVID-19 positive patients from March 18th-April 8th, 2020 with a malignant diagnosis were identified. A total of 61 (28%) cancer patients died from COVID-19 with a case fatality rate (CFR) of 37% (20/54) for hematologic malignancies and 25% (41/164) for solid malignancies. 6/11 (55%) lung cancer patients died from COVID-19 disease. Increased mortality was significantly associated with older age, multiple comorbidities, need for ICU support, and elevated levels of D-Dimers, LDH and lactate on multivariable analysis. Age-adjusted CFRs in cancer patients compared to non-cancer patients at our institution and NYC reported a significant increase in case fatality for cancer patients. These data suggest the need for proactive strategies to reduce likelihood of infection and improve early identification in this vulnerable patient population."],"journal":"Cancer Discov","authors":["Mehta, Vikas","Goel, Sanjay","Kabarriti, Rafi","Cole, Daniel","Goldfinger, Mendel","Acuna-Villaorduna, Ana","Pradhan, Kith","Thota, Raja","Reissman, Stan","Sparano, Joseph A","Gartrell, Benjamin A","Smith, Richard V","Ohri, Nitin","Garg, Madhur","Racine, Andrew D","Kalnicki, Shalom","Perez-Soler, Roman","Halmos, Balazs","Verma, Amit"],"date":"2020-05-03T11:00:00Z","year":2020,"_id":"32357994","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1158/2159-8290.CD-20-0516","locations":["D-Dimers"],"e_drugs":["Lactic Acid"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1666138495349948416,"score":192.5378},{"pmid":32278616,"pmcid":"PMC7129342","title":"Recommendations on management of the SARS-CoV-2 coronavirus pandemic (Covid-19) in kidney transplant patients.","text":["Recommendations on management of the SARS-CoV-2 coronavirus pandemic (Covid-19) in kidney transplant patients.","The SARS-CoV-2 (Covid-19) coronavirus pandemic is evolving very quickly and means a special risk for both immunosuppressed and comorbid patients. Knowledge about this growing infection is also increasing although many uncertainties remain, especially in the kidney transplant population. This manuscript presents a proposal for action with general and specific recommendations to protect and prevent infection in this vulnerable population such as kidney transplant recipients.","Nefrologia","Lopez, Veronica","Vazquez, Teresa","Alonso-Titos, Juana","Cabello, Mercedes","Alonso, Angel","Beneyto, Isabel","Crespo, Marta","Diaz-Corte, Carmen","Franco, Antonio","Gonzalez-Roncero, Francisco","Gutierrez, Elena","Guirado, Luis","Jimenez, Carlos","Jironda, Cristina","Lauzurica, Ricardo","Llorente, Santiago","Mazuecos, Auxiliadora","Paul, Javier","Rodriguez-Benot, Alberto","Ruiz, Juan Carlos","Sanchez-Fructuoso, Ana","Sola, Eugenia","Torregrosa, Vicente","Zarraga, Sofia","Hernandez, Domingo","32278616"],"abstract":["The SARS-CoV-2 (Covid-19) coronavirus pandemic is evolving very quickly and means a special risk for both immunosuppressed and comorbid patients. Knowledge about this growing infection is also increasing although many uncertainties remain, especially in the kidney transplant population. This manuscript presents a proposal for action with general and specific recommendations to protect and prevent infection in this vulnerable population such as kidney transplant recipients."],"journal":"Nefrologia","authors":["Lopez, Veronica","Vazquez, Teresa","Alonso-Titos, Juana","Cabello, Mercedes","Alonso, Angel","Beneyto, Isabel","Crespo, Marta","Diaz-Corte, Carmen","Franco, Antonio","Gonzalez-Roncero, Francisco","Gutierrez, Elena","Guirado, Luis","Jimenez, Carlos","Jironda, Cristina","Lauzurica, Ricardo","Llorente, Santiago","Mazuecos, Auxiliadora","Paul, Javier","Rodriguez-Benot, Alberto","Ruiz, Juan Carlos","Sanchez-Fructuoso, Ana","Sola, Eugenia","Torregrosa, Vicente","Zarraga, Sofia","Hernandez, Domingo"],"date":"2020-04-13T11:00:00Z","year":2020,"_id":"32278616","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.nefro.2020.03.002","keywords":["covid-19","immunosuppressed","inmunodeprimido","kidney transplantation","sars-cov-2","trasplante renal"],"topics":["Prevention"],"weight":1,"_version_":1666138491559346178,"score":187.12486}]}